Despite significant advances achieved in understanding the molecular mechanisms underlying PD, several limitations remain in translating NLRP3 inflammasome inhibitors and autophagy/mitophagy modulators into effective clinical therapies. Here, NLRP3 is linked to Parkinson disease.